All hinges on revenue Rebel. If you dont continue the uptick in...

All hinges on revenue Rebel. If you dont continue the uptick in sales, delays in commissioning the press, watch out given the BoD do not know how to run an lean organisation that is running solely on hand outs/loans/dilution and wont rationalise staff numbers given the financials. If at all, you'll see an increase in headcount to get the press up and running, onboarding an operations team and high level of costs allocated for trials before commericalisation - that is the real world. As an outsider looking in, if I was to re-enter it would once teething issues are sorted and the next round of CR which will reset the SP.